Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China

Objective: The purpose of this study was to estimate the cost-effectiveness of osimertinib for the first-line treatment of patients with EGFR-mutated advanced non-small-cell lung cancer (NSCLC) from the perspective of the Chinese healthcare system.Methods: A Markov model was developed to simulate th...

Full description

Bibliographic Details
Main Authors:	Yamin Shu, Yufeng Ding, Xucheng He, Yanxin Liu, Pan Wu, Qilin Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-09-01
Series:	Frontiers in Pharmacology
Subjects:	cost-effectiveness analysis first-line treatment FLAURA trial non-small-cell lung cancer osimertinib
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.920479/full

Similar Items

Third generation EGFR TKIs: current data and future directions
by: Chee-Seng Tan, et al.
Published: (2018-02-01)

Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an <i>EGFR</i>-Activating Mutation
by: Shigetoshi Nishihara, et al.
Published: (2022-07-01)

Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
by: Fionnuala Crowley, MB BCh BAO, et al.
Published: (2022-01-01)

AZ12756122, a novel fatty acid synthase inhibitor, decreases resistance features in EGFR-TKI resistant EGFR-mutated NSCLC cell models
by: Emma Polonio-Alcalá, et al.
Published: (2022-12-01)

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer
by: Yufeng Li, et al.
Published: (2023-04-01)

Effectiveness comparison of third-generation EGFR-TKI as initial and sequential therapy in adjuvant treatment for EGFR mutation-sensitive stage IIIA non-small cell lung cancer after surgery
by: Wenyan Ma, et al.
Published: (2023-11-01)

Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC
by: Judith L. Gulikers, MSc, et al.
Published: (2024-04-01)

Inhibition of PLK1 Destabilizes EGFR and Sensitizes EGFR-Mutated Lung Cancer Cells to Small Molecule Inhibitor Osimertinib
by: Carolien Eggermont, et al.
Published: (2023-05-01)

Adenovirus pneumonia mimicking osimertinib‐induced pneumonitis in a patient with advanced NSCLC with EGFR mutation: A case report
by: Toru Imai, et al.
Published: (2024-03-01)

Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC
by: M. Jebbink, MD, et al.
Published: (2023-04-01)

Neoadjuvant osimertinib and chemotherapy for stage IIIA primary pulmonary carcinosarcoma with EGFR 19DEL mutation: A case report
by: Hongming Wang, et al.
Published: (2023-03-01)

Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction
by: Shuhei Suzuki, et al.
Published: (2019-07-01)

Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States
by: Gengwei Huo, et al.
Published: (2024-03-01)

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
by: Kai Fu, et al.
Published: (2022-12-01)

Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis
by: Jie Wang, MD, PhD, et al.
Published: (2024-02-01)

Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040)
by: Tomoya Fukui, et al.
Published: (2022-12-01)

Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib
by: Wang L, et al.
Published: (2023-10-01)

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
by: Jingran Ji, MD, et al.
Published: (2023-03-01)

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience
by: A.J. Piper-Vallillo, MD, et al.
Published: (2022-06-01)

Pulmonary Pleomorphic Carcinoma Harboring EGFR Mutation Successfully Treated with Osimertinib: A Case Report
by: Yukari Kano, et al.
Published: (2022-05-01)

Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation
by: Kana Watanabe, et al.
Published: (2023-08-01)

Acquired Resistance to Osimertinib in <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?
by: Elisa Bertoli, et al.
Published: (2022-06-01)

Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report
by: Markus Falk, et al.
Published: (2023-09-01)

Efficacy of osimertinib in patients with EGFR‐mutation positive non‐small cell lung cancer with malignant pleural effusion
by: Ayu Kiritani, et al.
Published: (2024-02-01)

A case report: Response to Osimertinib in non-small cell lung cancer patient with uncommon EGFR mutation
by: Daniel J. Craig, et al.
Published: (2022-12-01)

PD‐L1 blockade by immune checkpoint inhibitors impairs sensitivity to osimertinib in EGFR‐mutant non‐small cell lung cancer cells
by: Dantong Sun, et al.
Published: (2022-12-01)

Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma
by: Chul Kim, et al.
Published: (2021-07-01)

Development of Liposomal Vesicles for Osimertinib Delivery to EGFR Mutation—Positive Lung Cancer Cells
by: Paulina Skupin-Mrugalska, et al.
Published: (2020-09-01)

CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC
by: Lee ATM, et al.
Published: (2023-04-01)

NCOA-RET fusion as a secondary resistance mechanism to osimertinib in complex EGFR-mutated lung adenocarcinoma: Case report and review of literature
by: Alberto P. Romagnolo, et al.
Published: (2023-06-01)

Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations
by: Yuki Takeyasu, MD, et al.
Published: (2024-02-01)

Relationship of EGFR-TKI Targeted Therapy and Pyroptosis in Non-small Cell Lung Cancer
by: CHEN Jiachen, et al.
Published: (2023-12-01)

Osimertinib for an Advanced NSCLC Patient with Two Common EGFR Mutations and a Concomitant MET Exon 14 Skipping Mutation: A Case Report
by: Liu Z, et al.
Published: (2023-07-01)

Osimertinib versus platinum-pemetrexed in patients with previously treated EGFR T790M advanced non-small cell lung cancer: An updated AURA3 trial-based cost-effectiveness analysis
by: Yin Shi, et al.
Published: (2022-10-01)

Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC
by: Michael Cekay, et al.
Published: (2023-08-01)

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation
by: Akihiro Yoshimura, et al.
Published: (2019-03-01)

Adenocarcinoma Harboring EGFR-RAD51 Fusion Treated With Osimertinib: A Case Report
by: Sunny Y. Lai, MD, et al.
Published: (2024-04-01)

SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma
by: Patricia L. Theard, et al.
Published: (2024-03-01)

UBL3 Interacts with Alpha-Synuclein in Cells and the Interaction Is Downregulated by the EGFR Pathway Inhibitor Osimertinib
by: Bin Chen, et al.
Published: (2023-06-01)

Case report: an initially unresectable stage III pulmonary sarcomatoid carcinoma qith EGFR mutation achieving pathological complete response following neoadjuvant therapy with osimertinib plus chemotherapy
by: Xiguang Liu, et al.
Published: (2022-11-01)